Proposed Methodologies For EU Joint Clinical Assessment Are Threat To ATMPs and Rare Disease Patients

Sixteen out of 18 EU-approved advanced therapy medicinal products would fail to pass an EU-wide joint clinical assessment because proposed methodologies are unsuitable for such products, according to the Alliance for Regenerative Medicine.